natgillin/translations-raw huggingface dataset:
According to another embodiment the carboxylic groups of the at least one carboxymethylcellulose are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or dining the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 6, gdje su karboksilne skupine barem jedne karboksimetilceluloze barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3PO,, ili kiselo reaktivne soli kao što je Na»HPOy, poželjno CaHPOxy.
The present invention relates to compounds of general formula (I) 
1. Spoj s općom formulom (I) R8"
(c.) a group of the formula (d.) ring AH, wherein ring AH is C3-C6 cycloalkyl or phenyl, wherein ring AH is unsubstituted or substituted by 1 to 3 moieties independently selected from halo or C1-C3alkyl; 
(c.) grupa formule [image] (d.) prsten AH, gdje je prsten AH C3-C6 cikloalkil ili fenil, pri čemu je prsten AH nesupstituiran ili je supstituiran sa 1 do 3 komponente nezavisno odabrane između halo ili C1-C3 alkil;
The present invention also relates to a self-extinguishing expandable composition of vinyl aromatic polymers and/or copolymers comprising: 
Samougasiva ekspandabilna mješavina vinilaromatskih polimera i/ili vinilaromatskih kopolimera, koja sadrži:
The invention concerns compounds of Formula (I) 
Spoj s formulom (I) naznačen time da:
C1-C6 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, O—C1-C5 alkyl, OPO3−2M2, OP(O)(OH)2, OC(O) alkyl, and OC(O)O-alkyl where M is a monovalent metal cation; and cycloalkyl optionally substituted with one or more substituents selected from the group consisting of OH and O—C1-C5 alkyl provided that no more than one oxygen is attached to any carbon; or R10 and R10′, together with the nitrogen to which they are attached, may form a heterocycle selected from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl; 
svaki R10 i R10' je neovisno odabran iz skupine koju čine H; C1-C6 alkil nesupstituiran ili supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine OH, O-C1-C5 alkil, OPPO3-2M2, OP(O)(OH)2, OC(O)-C1-C6 alkil, te OC(O)O-C1-C6 alkil gdje M je jednovalentni metalni kation; i C3-C18 cikloalkil nesupstituiran ili supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine OH i O-C1-C5 alkil pod uvjetom da na bilo koji ugljik nije vezan više od jednog kisika; ili R10 i R10', zajedno s dušikom na koji su oni vezani može tvoriti heterocikl;
The rAAV vector according to any preceding claim, wherein the at least a first nucleic acid segment is further operably linked to a post-transcriptional regulatory sequence or a polyadenylation signal, and preferably to a woodchuck hepatitis virus post-transcription regulatory element. 
rAAV vektor prema bilo kojem od zahtjeva 3 do 6, naznačen time da je barem prvi segment nukleinske kiseline dodatno operativo vezan na post-transkripcijsku regulirajuću sekvencu ili poliadenilacijski signal, te poželjno na post-transkripcijskom regulatornom elementu virusnog hepatitisa svisca.
resolving, by the user terminal, the uplink resource index from the ul grant; and performing, by the user terminal, a resource grant on the more than one uplink subframes corresponding to the uplink resource index. 
Postupak prema zahtjevu 1, naznačen time da se nadalje sastoji od: primanja, na korisničkom terminalu, odobrenja uzlazne veze koje prenosi indeks resursa za uzlaznu vezu;
There are several ways of granulation or agglomeration, which are suitable for the sugar replacement according to the present invention. 
Postoji nekoliko načina granuliranja ili aglomeracije, prikladnih za zamjenu za šećer u ovom izumu. HR P20080437 T3
The mixture was applied on a chromated steel substrate (0.6 mm thick) with a 16 µm wire bar applicator to give a dry film thickness of 10 µm. 
Smjesa je nanesena na kromiranu čeličnu podlogu (debljine 0,6 mm) pomoću uređaja sa čeličnim kistom od 16 um, čime je dobiven suhi film debljine 10 um.
A process as in claim 12 wherein L-alaninamide, D-alaninamide or their racemic mixture is employed as an acid addition salt thereof in the presence of a base in an amount sufficient to set free L-alaninamide, D-alaninamide or their racemic mixture from its salt. 
Postupak kao što je u patentnom zahtjevu 12, naznačeno time da se L-alaninamid, D-alaninamid ili njihova Tacemična smjesa primjenjuje kao njihova sol nastala adicijom kiseline u prisutnosti baze u količini koja je dovoljna da se iz njihove soli oslobodi IL-alaninamid, D-alaninamid ili njihova racemična smjesa.
The pharmaceutical composition according to claim 1, wherein the coating agent is hypromellose. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je sredstvo za oblaganje hipromeloza.
The dosage form of any one of claims 1-3, wherein the core is in the form of a tablet, wherein the content of rasagiline is 0.5 mg and the tablet comprises 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, 3.5 mg of hypromellose, 4.0 mg of methacryllic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, 1.9 mg of talc extra fine, and 2.0 mg of a color coating agent. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 0,5 mg, a tableta sadrži 45,5 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
Suitable protecting groups are known to those skilled in the art. 
Pogodne zaštitne skupine poznate su stručnjacima.
Cell density and productivity achieved with cells grown on Fibra-Cel ® disks can be up to ten times higher than with cells growing on microcarriers. 
Stanična gustoća te produktivnost koja je postignuta sa stanicama koje rastu na diskovima Fibra-Cel" može biti i do deset puta veća u usporedbi s onom koja je postignuta kada stanice rastu samo na mikronosačima.
In an additional method aspect, the invention provides a process for preparing a compound of formula (I′) wherein R1, R2, R4, and R5 are defined as in formula (I), or a salt or stereoisomer thereof, the process comprising reacting a compound of formula (IV): 
A2 sa spojem formule (IX): m pri čemu su R', R', R* i R? definirani jednako kao u Patentnom zahtjevu 1; ili njihova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time, da postupak obuhvaća izlaganje spoja formule (IV) reakciji:
The combination of claim 1 wherein the compound of formula (I) has the structure: 
Kombinacija prema patentnom zahtjevu 1 pri čemu spoj formule (1) ima strukturu: 3.
The resulting precipitate is filtered and dried under high vacuum at 50°C to yield the titled compound as a white powder. 
Dobiveni talog se odfiltrira i osuši pod visokim vakuumom pri 50"C, čime se dobije naslovni spoj kao bijeli prah.
The filler and the resin are mixed and are then ready for use. 
Punilo i smola su miješani te su bili spremni za upotrebu.
amino acid sequences that have no more than 3, preferably no more than 2, more preferably no more than 1 amino acid difference with one of SEQ ID NO's: 60-76, provided that: 
sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 60-76, pod uvjetom da:
Bottle 20 can be made of any of a number of materials. 
Boca 20 može biti izrađena od raznih materijala.
A pharmaceutical composition according to any one of claims 1-28, wherein such single dose form is a solid formulation adapted for oral administration. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-31, naznačena time što je takav pojedinačni dozni oblik čvrsta formulacija prilagođena za oralnu primjenu.
The method according to claim 1, wherein the asthma is selected from the group consisting of allergic and non-allergic asthma. 
Spoj sukladno zahtjevima 1 do 3 za liječenje alergijskih i nealergijskih bolesti dišnih puteva.
The solid dosage forms (e.g.; tablets, capsules etc.) can be coated or un-coated, but typically have a coating, for example a protective film coating (e.g. a wax or varnish) or a release controlling coating. 
Kruti dozirni oblici (na primjer tablete, kapsule i slično) mogu biti prevučene ili ne, ali obično imaju prevlaku, na primjer zaštitnu film prevlaku (na primjer vosak ili lak) ili imaju prevlaku za kontrolu oslobađanja.
Unlike most other epilepsies, photosensitive epilepsy is a reflex epilepsy and epileptiform discharges can be evoked at any time by IPS in the laboratory. 
Za razliku od mnogih drugih epilepsija, fotosenzitivna epilepsija je refleksna epilepsija i epileptična pražnjenja se mogu izazvati u bilo koje vrijeme putem IPS- a u laboratoriju.
The method according to any of the preceding claims, wherein the flame retardant chemical composition comprises a phosphate compound, such as ammonium phosphate, potassium phosphate, and sodium phosphate. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da kemijsko sredstvo za usporavanje plamena sadržava fosfatni spoj, na primjer amonijev fosfat. HR P20151044 T1
wherein X3 is chloro, bromo, or iodo, or preparing the compound of Formula IIa: by a process comprising reacting a compound of Formula IId: with an acid of formula HX'; 
pri čemu X3 je klor, brom, ili jod, ili pripremanje spoja s formulom IIa: [image] postupkom koji obuhvaća reakciju spoja s formulom IId: [image] s kiselinom prema formuli HX';
The vector of claim 3, wherein the polypeptide comprises SEQ ID NO: 3 or SEQ ID NO: 5. 
Molekula nukleinske kiseline prema zahtjevu 4, naznačena time što kodirani polipeptid sadrži SEQ ID NO: 3 ili SEQ ID NO: 5.
A compound according to any one of claims 1 to 10 wherein R4 and R5 together with the nitrogen atom to which they are attached form a radical selected from the group consisting of 1,1-dioxide-thiomorpholinyl, azetidinyl, 2,3-dihydroisoindol-1-yl, thiazoldin-3-yl, 1,2,3,6-tetrahydropyridyl, hexahydro-1 H -azepinyl, hexahydro-1 H -1,4-diazepinyl, hexahydro-1,4-oxazepinyl, 1,2,3,4-tetrahydroisoquinolin-2-yl, 2,5-diazabicyclo[2.2.1]heptyl, each of said rings optionally substituted with C1-6alkyl or arylC1-6alkyl. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time da R" i R* zajedno sa atomom dušika na kojeg su vezani tvore radikal odabran iz skupine koju čine 1,1-dioksid-tiomorfolinil, azetidinil, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-14-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokvinolin-2-il, 2,5-diazabiciklo[2.2.1]heptil, svaki od navedenih prstena po izboru supstituiran sa C,.salkil ili arilC, .salkil,
A partitioning wall may separate the primary and secondary chambers within the mouthpiece and at least one air bypass aperture may extend through the partitioning wall to communicate the primary chamber with the secondary chamber. 
Inhalator prema zahtjevu 10, gdje se barem jedan otvor za prolaz zraka (35) pruža kroz razdjelni zid (33) radi komunikacije primarne komore (31) sa sekundarnom komorom (32).
substitution at nucleotide position 2889; G to A. In a preferred embodiment the marker vaccine of the present invention is characterised in that the viral amino acid sequence exhibits one or more of the following substitutions: 
Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni aminokiselinski slijed izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj,Riems" virusa:
A composition for use according to claim 9 wherein the dose is taken from 0.8 to 3 hours prior to the patient's bedtime; and/or wherein the dose is taken once daily. 
Pripravak za uporabu prema zahtjevu 8, naznačen time da se doza uzima od 0,8 do 3 sata prije spavanja pacijenta; i/ili pri čemu se doza uzima jednom dnevno.
A magnetic drive according to Claim 13, wherein the driving member is disposed coaxially with the electric motor and wherein the driving member and the electric motor share a common shaft. 
Magnetni pogon prema patentnom zahtjevu 12, naznačen time što pogonski element je smješten koaksijalno s elektromotorom i pri čemu pogonski element i elektromotor imaju zajedničku osovinu.
Polygraphic recordings were started 7 days after surgery. 
Poligrafska mjerenja započela su 7 dana nakon kirurškog zahvata.
The mixture was stirred at room temperature for 2h, then at 60°C for 2h. 
Smjesa se miješa na sobnoj temperaturi tijekom 2 h, te tada na 600C tijekom 2 h.
combining a composition comprising an aprotic solvent and a hydroxy-terminated, water-soluble polymer having the following structure: 
(a) sjedinjavanje kompozicije, koja sadrži aprotonsko otapalo i vodotopljivi polimer sa hidroksi grupom na kraju lanca koji ima slijedeću strukturu:
Accordingly, in one preferred embodiment, the invention provides an orally administered pharmaceutical composition comprising heterologous platelet-rich plasma for use in the treatment or prevention of functional disability and/or pain associated with osteoarthritis. 
Farmaceutski pripravak koji sadrži plazmu bogatu trombocitima (PRP) dobivenu iz heterolognih izvora za uporabu u liječenju ili prevenciji boli povezane sa bolestima zglobova i tetiva, poremećajima ili ozljedama, pri čemu se spomenuti pripravak primjenjuje oralno.
Solar concentrator according to Claim 1, characterized in that the nanocrystals (2) comprise quaternary semiconductors. 
Koncentrator sunčevog zračenja u skladu s patentnim zahtjevom 1, naznačen time što nanokristali (2) sadrže kvaternarne poluvodiče.
The method of claim 1 wherein water content has been added to the waste in order to achieve an appropriate non-water content. The method of claim 4 wherein an appropriate non-water content is achieved by adding to the MSW a constant mass ratio of water between 0.5 and 2.5 kg water per kg MSW. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se otpadu dodaje sadržaj vode kako bi se postiglo prikladan sadržaj nevodenih tvari, i/ili što se prikladan sadržaj nevodenih tvari postiže dodavanjem u MSW konstantnog masenog omjera vode između 0,5 1 2,5 kg vode po kg MSW.
In some cases, angle a1 has a value within a range from about 10 degrees to about 60 degrees. 
Kristal violet prisutno u dovoljnoj količini da se dobiju koncentracije od oko 6 uM do oko 10 uM u uvjetima bojenja;
The juice extraction module according to claim 1, wherein the input portion (410) defines a " " shaped material input path. 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 1, naznačen time što dio za ubacivanje (410) određuje put ubacivanja materijala u obliku " L",
The method of claim 7, wherein the target cell is a human cell infected by a human pathogen and the agent binds an epitope of the human pathogen. 
(Cc) humana stanica zaražena humanim patogenom, a terapijsko antitijelo se specifično vezuje za epitop humanog patogena; ili
The rotary machine according to claim 1, wherein the radially extending flange portions on radially extending surfaces have a fine clearance relative to an internal circumferential surface of the respective end covers. 
Rotacijski motor prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time da radijalno prošireni dijelovi s prirubnicama (2a', 2b') na svojoj obodnoj površini imaju fini razmak u odnosu na unutarnju obodnu površinu odgovarajućih završnih pokrova (5a, 5b).
an agent for preserving BSH activity, optionally inulin, trealose, maltodextran, yeast extract, polyethylene glycol, glycerol, lipid, emulsified fat, a dairy product, glucose, fructose, sucrose, a poly sugar, anhydrobiosis, a polycosanol, polyethlylene glycol (PEG), a plant sterol, a plant stanol or an omega fatty acid; 
(d) agens za očuvanje BSH aktivnosti, opcionalno inulin, trehaloza, maltodekstran, ekstrakt kvasca, polietilen glikol, glicerol, lipid, emulzirana masnoća, dijetni proizvod, glukoza, fruktoza, sukroza, poli šećer, anhidrobioza, polikozanol, polietilenglikol (PEG), biljni sterol, biljni stanol ili omega masna kiselina;
The resulting mixture stirred an additional 1 h and was quenched with 1N HCl. 
Dobivena smjesa je miješana još 1 sat i ugašena je sa IN HCI.
wherein the underlined nucleotide refers to a nucleotide having or not having a phosphorothioate or methylphosphonate backbone, the linked L′ is selected from the group consisting of hexaethyleneglycol, teradeoxythymidylate (T4) and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; m is 1, L is a carboxamido oligoethylene glycol and C is selected from the group consisting of dioleoyl, octadecyl, folic acid, tocopherol and cholesterol. 
(Ile), gdje se podcrtani nukleotid odnosi na nukleotid koji ima ili koji nema fosforotioatnu ili metilfosfonatnu okosnicu, vezani L' se bira iz skupine koju čine heksaetilen-glikol, tetradeoksitimidilat (T4) 1 2,19-bis(fosfor)-8-hidraza-1- hidroksi-4-oksa-9-oksononadekan; m je 1, L je karboksamidooligoetilen-glikol, a C se bira iz skupine koju čine dioleo1l, oktadecil, folna kiselina, tokoferol i kolesterol.
The method of claim 5, wherein one or more of: 
Jedna ili više nukleinskih kiselina, naznačene time, da obuhvaćaju sljedeće:
The other terminal of coil 21 is routed to the parallel of a regulation zener 92 and a filtering capacitor 91, with negative terminals connected to ground 100 and the positive ones to a conductor 110 forming the positive of a second supply voltage (in this case 5.1V) feeding both the logic unit 50 and an operational amplifier 90 (for instance a LPV321). 
Drugi priključak zavojnice 21 je spojen u paralelu s regulacijske zener diode 92 i filtrirajućeg kondenzatora 91, s time da su pozitivni priključci spojeni na masu 100, a pozitivni na vodič 110, tvoreći pozitivni (+) priključak drugog izvora napajanja (u ovom slučaju 5.1 V), napajajući i logičku jedinicu 50, i operacijsko pojačalo 90 (npr. LPV321).
is hydrogen or a radical of formula 
R* je vodik ili radikal sa formulom
The compound for use according to claim 8, wherein the inflammation is associated with a disorder or disease selected from Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular edema, ileitis, ulcerative colitis, Barrett's syndrome, Crohn's disease, neurodegeneration, Alzheimer's disease, multiple sclerosis, Huntington's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, amyotrophic lateral sclerosis, encephalitis, muscular dystrophy, dermatomositis, inclusion body myositis, polymyositis, or cachexia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je upala povezana s poremećajem ili bolešću koju se bira između dijabetesa tip II, otpornost na inzulin, kardiovaskularna bolest, aritmija, ateroskleroza, bolest koronarnih arterija, hipertrigliceridemija, dislipidemija, retinopatija, nefropatija, neuropatija, makularni edem, ileitis, ulcerozni kolitis, Barrettov sindrom, Crohnova bolest, neurodegeneracija, Alzheimerova bolest, multipla skleroza, Huntingtonova bolest, zarazni meningitis, encefalomijelitis, Parkinsonova bolest, amiotrofna lateralna skleroza, encefalitis, mišićna distrofija, dermatomozitis, miozitis s inkuzijskim tijelima, polimiozitis ili kaheksija.
A pharmaceutical combination of Claim 25 wherein the anti-anxiety agent is selected from benzodiazepines selected from diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam; 5HT1A receptor agonists selected from buspirone, flesinoxan, gepirone and ipsapirone; and corticotropin releasing factor antagonists. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je sredstvo protiv anksioznosti odabrano od benzodiazepina odabranih od diazepam, lorazepam, oksazepam, alprazolam, klordiazepoksid, klonazepam, klorazepat, halazepam i prazepama, agonista SHTIA receptora odabranih od buspiron, flesinoksan, gepiron i ipsapirona te antagonista faktora za oslobađanje kortikotropina.
These isoforms vary in their ability to bind IL-18. 
Ove se izoforme razlikuju u svojoj sposobnosti da vežu IL-18.
A maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); 
(ili) period održavanja pri čemu se primjenjuje Kladribin i pri čemu ukupna doza Kladribina koja se daje tijekom perioda održavanja je niža od ili jednaka ukupnoj dozi Kladribina dosegnutoj na završetku perioda indukcije
A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of the compound according to claim 1 . 
Spoj ili sol prema patentnom zahtjevu 5 naznačen time što je za upotrebu u postupku liječenja ili smanjenja intenziteta boli kod subjekta s kroničnom boli, crijevnom boli, neuropatskom boli, mišićno-skeletnom boli, akutnom boli, upalnom boli, boli zbog raka, idiopatskom boli, boli nakon kirurške intervencije, visceralnom boli, boli zbog multiple skleroze, Charcot-Marie-Tooth sindroma, inkontinencije, patološkog kašlja ili srčane aritmije.
12 illustrates that 42-O-(D-Fructosylcarbonyl)rapamycin prolonged survival of the graft over the vehicle as did rapamycin at the 2.5 mg/kg/day dose level. 
Slika 12 prikazuje kako je 42-O(D-fruktozilkarbonil)rapamicin produljio preživljenje transplantata u odnosu na nosač, kao što je djelovao i rapamicin u dozi od 2,5 mg/kg/dan.
The method of claim 10 wherein the dosage form on first commercial sale contains no more than about 0.5% by weight of FTU. 
Postupak prema patentnom zahtjevu 10, naznačen time što oblik doze prilikom prve komercijalne prodaje sadrži ne više od oko 0.5 težinskih % FTU.
The compound of claim 3, wherein G2 is selected from the group below: wherein m is 1; 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da je G> izabran iz skupine ispod:
Sugar replacement composition according to claim 24, whereby the low intensity sweetener is selected from the group consisting of maltitol, isomalt, lactitol, erythritol, polyols or a is combination thereof. 
Sastavina koja zamjenjuje šećer iz patentnog zahtjeva #20, gdje se sladilo male slatkoće bira iz skupine koju čine maltitol, izomalt, lacitol, eritriol, polioli, poliglicitolni sirupi ili praškovi, hidrolizati hidrogeniranog škroba (poliglicitolni sirupi) i/ili glicerin, ili njihove kombinacije.
5 and 6 . These results illustrate that cation exchange material can be used to (further) decolourise caramel, while retaining a large part of the UV absorption capacity. 
Ti rezultati pokazuju da se kation izmjenjivački materijal može upotrijebiti za (daljnje) obezbojenje karamele, dok se istovremeno zadržava velik dio kapaciteta UV apsorpcije.
Also in this case the reaction temperature is preferably in the range of 10 to 48° C., more preferably in the range of 20 to 32° C. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što temperatura je u rasponu od 20 do 32 "C.